{
    "clinical_study": {
        "@rank": "6415", 
        "arm_group": [
            {
                "arm_group_label": "Viagra", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra\u00ae tablet) 50 mg as a single oral dose under fasted conditions"
            }, 
            {
                "arm_group_label": "ODT without water", 
                "arm_group_type": "Experimental", 
                "description": "Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions"
            }, 
            {
                "arm_group_label": "ODT with water", 
                "arm_group_type": "Experimental", 
                "description": "Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the bioequivalence of Sildenafil ODT 50 mg without\n      water to Japanese commercial oral tablet of sildenafil citrate (Viagra\u00ae tablet) 50 mg under\n      fasted conditions."
        }, 
        "brief_title": "Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Japanese male subjects between the ages of 20 and 55 years.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n        Exclusion Criteria:\n\n          -  Baseline orthostatic hypotension defined as a >=20 mm Hg reduction in systolic blood\n             pressure (SBP), a >=10 mm Hg reduction in diastolic blood pressure (DBP) or the\n             development of significant postural symptoms (dizziness, lightheadedness, vertigo)\n             when going from the supine to standing position.\n\n          -  Subjects who are currently prescribed or taking nitrates or nitric oxide donors in\n             any form on either a regular or intermittent basis."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737203", 
            "org_study_id": "A1481315"
        }, 
        "intervention": [
            {
                "arm_group_label": "Viagra", 
                "description": "50 mg tablet on Day 1 of each period", 
                "intervention_name": "Viagra", 
                "intervention_type": "Drug", 
                "other_name": "sildenafil citrate"
            }, 
            {
                "arm_group_label": "ODT without water", 
                "description": "50 mg tablet on Day 1 of each period", 
                "intervention_name": "sildenafil ODT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ODT with water", 
                "description": "50 mg tablet on Day 1 of each period", 
                "intervention_name": "sildenafil ODT", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Viagra", 
            "ODT", 
            "bioquivalence"
        ], 
        "lastchanged_date": "November 26, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481315&StudyName=Bioequivalence%20Study%20For%20Orally-Disintegrating%20Tablet%20Of%20Sildenafil"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Minato-ku", 
                    "country": "Japan", 
                    "state": "Tokyo"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Sildenafil 50 Mg Orally-Disintegrating Tablet With Or Without Water To Viagra\u00ae 50 Mg Oral Tablet With Water Under Fasted Condition", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - \u221e)]", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737203"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }, 
            {
                "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "measure": "Diastolic and Systolic Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "measure": "12-lead electrocardiogram (ECG)", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "measure": "Pulse rate (PR)", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "measure": "Number of Participants With Laboratory Test Values of Potential Clinical Importance", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "measure": "Mean Residence Time(MRT)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.05, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14 h post-dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}